ARK Investment Management Discloses 3.2M Share Stake in Nurix Therapeutics

TL;DR

**ARK just revealed a big stake in Nurix, signaling bullish sentiment.**

AI Summary

ARK Investment Management LLC, a prominent investment firm, reported on January 29, 2024, that it beneficially owns 3,194,999 shares of Nurix Therapeutics, Inc. (NRIX) common stock as of December 31, 2023. This represents a significant stake, giving ARK sole voting and dispositive power over these shares. This matters to investors because ARK's substantial holding signals their conviction in Nurix's future, potentially influencing other investors and the stock's perception.

Why It Matters

A major institutional investor like ARK Investment Management taking a significant position can be seen as a vote of confidence, potentially attracting more investor interest and upward price momentum for Nurix Therapeutics.

Risk Assessment

Risk Level: low — This filing indicates a large institutional investment, which generally reduces risk by showing confidence in the company.

Analyst Insight

A smart investor would research Nurix Therapeutics, Inc.'s fundamentals and recent news to understand why ARK Investment Management LLC has taken such a significant position, potentially considering it as a positive signal for the stock.

Key Numbers

• 3,194,999 — Shares Beneficially Owned (Represents ARK Investment Management LLC's total holding in Nurix Therapeutics, Inc.)
• $0.001 — Par Value per Share (The nominal value of Nurix Therapeutics, Inc. common stock.)

Key Players & Entities

• ARK Investment Management LLC (company) — the reporting person and institutional investor
• Nurix Therapeutics, Inc. (company) — the subject company whose shares were acquired
• 3,194,999 (dollar_amount) — number of shares beneficially owned
• December 31, 2023 (date) — date of the event requiring the filing
• January 29, 2024 (date) — filing date of the SC 13G
• Delaware (company) — place of organization for ARK Investment Management LLC

Forward-Looking Statements

• ARK Investment Management LLC will maintain or increase its stake in Nurix Therapeutics, Inc. in the near future. (ARK Investment Management LLC) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

• tm244117d1_sc13g.htm (SC 13G) — 50KB
• 0001104659-24-007679.txt ( ) — 52KB

(a) Name of issuer

Item 1(a) Name of issuer: Nurix Therapeutics Inc.

(b) Address of issuer's

Item 1(b) Address of issuer's principal executive offices: 1700 Owens Street, Suite 205 San Francisco, CA 94158

(a) Name of person filing

Item 2(a) Name of person filing: ARK Investment Management LLC

(b) Address or principal

Item 2(b) Address or principal business office or, if none, residence: ARK Investment Management LLC 200 Central Avenue St. Petersburg, FL 33701

(c) Citizenship

Item 2(c) Citizenship: Delaware, United States

(d) Title of class of

Item 2(d) Title of class of securities: Common Shares, par value $0.001 per share

(e) CUSIP No

Item 2(e) CUSIP No.: 67080M103

If this statement is filed

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8); (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ CUSIP No. 67080M103 13G Page 4 of 5 Pages

Ownership

Item 4. Ownership (a) Amount beneficially owned: 3,194,999 (b) Percent of class: 6.59% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 3,194,999 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 3,194,999 (iv) Shared power to dispose or to direct the disposition of: 0

Ownership of 5 Percent or

Item 5. Ownership of 5 Percent or Less of a Class. Not applicable.

Ownership of More than 5 Percent on Behalf of Another Person

Item 6. Ownership of More than 5 Percent on Behalf of Another Person. To the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the shares which represents more than five percent of the number of outstanding class of the shares. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group. Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group. Not applicable. CUSIP No. 67080M103 13G Page 5 of 5 Pages

Certifications

Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. The reporting persons agree that this statement is filed on behalf of each of them. Dated: January 29, 2024 ARK Investment Management LLC By: /s/ Kellen Carter Name: Kellen Carter Title: Chief Compliance Officer

View Full Filing

View this SC 13G filing on SEC EDGAR